Please login to the form below

Not currently logged in
Email:
Password:

Tecentriq

This page shows the latest Tecentriq news and features for those working in and with pharma, biotech and healthcare.

Hemlibra off to a flyer as Roche raises 2019 forecasts

Hemlibra off to a flyer as Roche raises 2019 forecasts

However, new drugs including Ocrevus (ocrelizumab) for multiple sclerosis, cancer immunotherapy Tecentriq (atezolizumab) and new haemophilia drug Hemlibra (emicizumab) acted as a buffer. ... Tecentriq meanwhile is gathering pace after a slow start on the

Latest news

  • CHMP recommends new Keytruda dosing schedule CHMP recommends new Keytruda dosing schedule

    Other PD-1/PD-L1 inhibitors approved for use are AstraZeneca’s Imfinzi, Pifzer and Merck’s Bavencio and Roche’s Tecentriq, and the latter is currently being explored in a

  • Keytruda adds another NSCLC approval in Europe Keytruda adds another NSCLC approval in Europe

    Keytruda's closest competitor in first line NSCLC treatment is Roche's Tecentriq, which recently gained EU approval for frontline combination use in non-squamous NSCLC, but it trails far behind

  • Celgene’s Abraxane fails pancreatic cancer trial Celgene’s Abraxane fails pancreatic cancer trial

    It secured another this week when the FDA cleared the drug in combination with Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) for triple-negative breast cancer – becoming the first immunotherapy regimen

  • Tecentriq gains first IO approval in triple negative breast cancer Tecentriq gains first IO approval in triple negative breast cancer

    Tecentriq (atezolizumab) can now be used in combination with chemotherapy (Celgene’s Abraxane, nab-paclitaxel) in adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) and whose tumours ... This is based on

  • Tecentriq combo gains European NSCLC approval Tecentriq combo gains European NSCLC approval

    Over half (56.4%) of participants in the Tecentriq combination arm also demonstrated tumour shrinkage compared to 40.2% those in the Avastin/Chemo group. ... Roche has a major programme of trials underway evaluating Tecentriq alone or in combination with

More from news
Approximately 39 fully matching, plus 55 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    2019. The only drug that has any realistic chance of challenging Keytruda in NSCLC is Roche’s Tecentriq. ... The Tecentriq chemo trial, IMpower132, is the most important head-to-head with Keytruda (in non-squamous NSCLC).

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    The therapy area is dominated by Merck’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    It’s not all been plain sailing, with BMS’ Opdivo (nivolumab) and Roche’s Tecentriq not doing as well as hoped in frontline NSCLC, revealing there are differences between checkpoint inhibitors – ... The drugmaker thinks Avastin may enhance

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics